Poliomyelitis leading to large-scale trials in the then Belgian Congo and the vaccination of seven million children in Poland against serotypes PV1 and PV3 between 1958 and 1960. The second inactivated polio virus vaccine was developed in 1952 by Jonas Salk at the University of Pittsburgh, and announced to the world on 12 April 1955. The Salk vaccine, or inactivated poliovirus vaccine, is based on poliovirus grown in a type of monkey kidney tissue culture (vero cell line), which is chemically inactivated with formalin. After two doses of inactivated poliovirus vaccine (given by injection), 90 percent or more of individuals develop
The Immune Response Corporation The Immune Response Corporation The Immune Response Corporation (IRC), founded by Jonas Salk and Kevin Kimberlin and based in Carlsbad, California, pioneered immunotherapeutic products. Francis Crick once said about Salk, “Few have made one discovery that has benefited humanity so greatly. Jonas was a man who, right to his last day, was actively in pursuit of another.” That pursuit was The Immune Response Corporation. Kimberlin “asked Salk to become lead scientific advisor for a new biotech company specializing in ‘anti-idiotypes,’ a novel vaccine technology.” Salk called the proposal “liberating.” The management team included CEO Jim Glavin, former CEO of Genetic